A review of 6 placebo-controlled scientific trials with 1,134 complete individuals concluded that cannabinoids (nabiximols, dronabinol, and THC/CBD) were being related to a better normal advancement on the Ashworth scale for spasticity in multiple sclerosis sufferers as opposed with placebo, Even though this did not achieve statistical significance